AbbVie has secured European Union approval for Boey, a short-acting botulinum toxin designed for faster onset and shorter duration than traditional formulations. The product represents Allergan's answer to market demand for flexibility in toxin dosing and patient preference for reversibility.
Regulatory
AbbVie Wins EU Approval for Boey, Its Short-Acting Botulinum Toxin
Allergan's rapid-onset neuromodulator clears European regulatory hurdle, expanding the toxin portfolio beyond standard-duration products.
1-YEAR MOVE
ABBV
▲11.6%
| Ticker | Company | 1-year change |
|---|---|---|
| ABBV | AbbVie (Allergan Aesthetics) | +11.6% |
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Boey's faster onset and shorter duration give practices a third toxin option—and AbbVie another revenue stream in an increasingly segmented market.
Boey's mechanism centers on rapid diffusion kinetics—the formulation achieves clinical effect faster and wears off sooner than standard toxins, positioning it for patients seeking trial treatments or those concerned about prolonged paralysis. In the EU, this approval expands AbbVie's toxin franchise beyond Botox and Dysport, giving prescribers another option to customize patient outcomes. The regulatory win matters for US practices because EU clearance typically precedes FDA submission and signals commercial viability; expect a 510(k) filing stateside within 12–18 months.
Source: original report ↗
Frequently asked questions
What is Boey botulinum toxin and how is it different from Botox?
Boey is a short-acting botulinum toxin formulation with rapid diffusion kinetics that produces clinical results faster and wears off sooner than standard toxins like Botox. It's designed for patients seeking trial treatments, reversibility, or flexibility in dosing rather than prolonged paralysis.
When will Boey be available in the United States?
AbbVie has secured EU approval for Boey, and a 510(k) FDA filing is expected within 12–18 months. EU clearance typically precedes US regulatory submission, so US availability will likely follow European launch.
Who is Boey botulinum toxin best for?
Boey is ideal for patients concerned about prolonged paralysis, those wanting to trial neuromodulator treatment before committing to longer-acting products, or patients who prefer the option of faster reversal. Its shorter duration makes it suitable for patients prioritizing flexibility and reversibility.
How does Boey's rapid onset work compared to traditional botulinum toxin?
Boey uses rapid diffusion kinetics in its formulation, allowing it to achieve clinical effect faster than traditional toxins while also wearing off sooner. This mechanism differentiates it from standard-duration products like Botox and Dysport.
What does AbbVie's Boey approval mean for medspa practices?
Boey expands AbbVie's toxin portfolio beyond Botox and Dysport, giving prescribers a third option to customize patient outcomes and treatment plans. The EU approval signals commercial viability and suggests the product will reach US practices within the next 12–18 months.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.